aTyr Pharma Inc (NASDAQ:LIFE) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $1.01.
A number of equities research analysts have recently weighed in on the stock. ValuEngine upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. William Blair reiterated a “market perform” rating on shares of aTyr Pharma in a research report on Tuesday, March 26th. Finally, Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research report on Friday, March 29th.
Shares of NASDAQ LIFE traded down $0.03 during midday trading on Monday, reaching $0.35. The company’s stock had a trading volume of 809,070 shares, compared to its average volume of 399,966. The company has a current ratio of 4.00, a quick ratio of 4.00 and a debt-to-equity ratio of 0.31. aTyr Pharma has a fifty-two week low of $0.31 and a fifty-two week high of $1.37. The stock’s 50 day moving average price is $0.49. The firm has a market cap of $15.47 million, a P/E ratio of -0.30 and a beta of 2.59.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Featured Story: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.